Oncolytics Biotech (NASDAQ:ONCY) Rating Lowered to Hold at Zacks Investment Research

Oncolytics Biotech (NASDAQ:ONCY) was downgraded by Zacks Investment Research from a “buy” rating to a “hold” rating in a note issued to investors on Thursday, Zacks.com reports.

According to Zacks, “Oncolytics Biotech, Inc. focuses on the discovery and development of pharmaceutical products for the treatment of a wide variety of human and companion pet cancers. The Company was formed to explore the oncolytic capability of the reovirus, a virus that preferentially replicates in cells with an activated Ras pathway, one of the most common family of genetic defects leading to cancer. “

A number of other analysts have also commented on the stock. ValuEngine lowered shares of Oncolytics Biotech from a “buy” rating to a “hold” rating in a research note on Wednesday, September 4th. Roth Capital initiated coverage on shares of Oncolytics Biotech in a research note on Wednesday, September 4th. They issued a “buy” rating and a $7.00 price target for the company.

Oncolytics Biotech stock traded down $0.04 during trading hours on Thursday, reaching $1.06. The stock had a trading volume of 632,400 shares, compared to its average volume of 203,859. The company has a debt-to-equity ratio of 0.08, a current ratio of 3.21 and a quick ratio of 3.21. The stock has a market cap of $28.51 million, a PE ratio of -1.29 and a beta of 2.11. Oncolytics Biotech has a 52 week low of $0.35 and a 52 week high of $2.79. The company has a fifty day simple moving average of $0.67 and a 200-day simple moving average of $1.23.

Oncolytics Biotech (NASDAQ:ONCY) last announced its quarterly earnings results on Tuesday, August 13th. The company reported ($0.19) EPS for the quarter. Research analysts predict that Oncolytics Biotech will post -0.91 earnings per share for the current fiscal year.

A hedge fund recently bought a new stake in Oncolytics Biotech stock. Verition Fund Management LLC purchased a new position in Oncolytics Biotech, Inc. (NASDAQ:ONCY) in the second quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund purchased 408,838 shares of the company’s stock, valued at approximately $695,000. Verition Fund Management LLC owned 2.01% of Oncolytics Biotech as of its most recent SEC filing. Hedge funds and other institutional investors own 2.31% of the company’s stock.

About Oncolytics Biotech

Oncolytics Biotech Inc, a development stage biopharmaceutical company, focuses on the discovery and development of pharmaceutical products for the treatment of cancer. The company is developing REOLYSIN, an immuno-oncology viral-agent that comprises three programs: chemotherapy combinations to trigger selective tumor lysis; immune modulator combinations to facilitate innate immune responses; and immuno-therapy combinations to produce adaptive immune responses.

Featured Article: Earnings Per Share

Get a free copy of the Zacks research report on Oncolytics Biotech (ONCY)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Oncolytics Biotech Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Oncolytics Biotech and related companies with MarketBeat.com's FREE daily email newsletter.



Comments


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on reddit